Cargando…

Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review

Background: PARP inhibitors have shown significant improvement in progression-free survival, but their costs cast a considerable financial burden. In line with value-based oncology, it is important to evaluate whether drug prices justify the outcomes. Objectives: The aim of the study was to systemat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Vivien Kin Yi, Yang, Runqing, Wong, Ian Chi Kei, Li, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313592/ https://www.ncbi.nlm.nih.gov/pubmed/35899114 http://dx.doi.org/10.3389/fphar.2022.891149

Ejemplares similares

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
por: Dong, Ruihong, et al.
Publicado: (2023)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021)

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
por: Zheng, Jingcao, et al.
Publicado: (2023)

Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking
por: Anjos, Suzana M., et al.
Publicado: (2012)

Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
por: Nagao, M, et al.
Publicado: (1991)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Current status of poly(ADP-ribose) polymerase inhibitors and future directions
por: Ohmoto, Akihiro, et al.
Publicado: (2017)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
por: Singh, Bijay, et al.
Publicado: (2020)

Role of poly(ADP-ribose) polymerases in male reproduction
por: Celik-Ozenci, Ciler, et al.
Publicado: (2013)

Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction
por: Wang, Qi, et al.
Publicado: (2018)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
por: Zhang, Jingsong
Publicado: (2014)

Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models
por: Ordway, Gregory A, et al.
Publicado: (2017)

Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
por: Hastak, Kedar, et al.
Publicado: (2017)

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide
por: Badawy, Abdulla A.-B.
Publicado: (2020)

Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study
por: Zhong, Sheng, et al.
Publicado: (2021)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Stability of centrosome numbers in poly(ADP-ribose) polymerase-1- and poly(ADP-ribose) glycohydrolase-deficient mouse ES cells
por: Ogino, Hideki, et al.
Publicado: (2004)

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
por: Zhao, Quanfeng, et al.
Publicado: (2022)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
por: Zhao, Quanfeng, et al.
Publicado: (2022)

Targeting poly(ADP-ribose) polymerase activity for cancer therapy
por: Mégnin-Chanet, Frédérique, et al.
Publicado: (2010)

Lipoxygenases and Poly(ADP-Ribose) Polymerase in Amyloid Beta Cytotoxicity
por: Strosznajder, Joanna B., et al.
Publicado: (2011)

Analysis of Poly(ADP-Ribose) Polymerases in Arabidopsis Telomere Biology
por: Boltz, Kara A., et al.
Publicado: (2014)

The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis
por: García, Samuel, et al.
Publicado: (2015)

Poly(ADP-Ribose) Polymerase-3 Regulates Regeneration in Planarians
por: Barghouth, Paul G., et al.
Publicado: (2020)

New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases
por: Ryu, Keun Woo, et al.
Publicado: (2015)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
por: Faraoni, Isabella, et al.
Publicado: (2019)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment
por: Zhao, Dehua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4c81hhbomugjiboep9t4lhkibe